Cellular reprogramming is the hottest topic in longevity science, with tech titans like Sam Altman investing in it. It's now ...

The outspoken longevity scientist David Sinclair has been predicting that one day, you’ll go to the doctor and get a ...

Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic editing platform that enables safe modification of multiple genes in primary ...

The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy next year ...

NewLimit Series C raises $435M led by Founders Fund as Armstrong-backed startup moves epigenetic therapies toward human ...

Resting brain stem cells hardly differ from normal astrocytes, which support the nerve cells in the brain. How can almost identical cells perform such different functions? The key lies in the ...

Lactate, once considered a metabolic waste product, is now recognized as a key regulator of cellular homeostasis and disease progression. In gynecological malignancies-including ovarian, cervical, and ...

Biotech startup NewLimit secured a major funding round after claiming a scientific breakthrough of a prototype medicine that ...

Longevity start-up NewLimit has raised an eye-watering $435 million to take its lead age reprogramming candidate into human ...